CellaVision AB (publ) (CEVI)
Free
No email, no account, no signup.
Pulling latest news for CellaVision AB (publ)…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
HOLD
Sentiment
4/10
Risk
5/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has clearly deteriorated after the Q1 miss and uncertainty around how long the EMEA inventory reset will weigh on sales (with spillover risk into Q2). Positives include strong cash flow/cash position, continued growth in Americas/APAC, and the bone marrow application expanding the addre...
Exchange
Nasdaq Stockholm
Type
Technology
Sector
Medtech diagnostics (digital hematology)
Market Cap
$389M
Market sentiment
Sentiment has clearly deteriorated after the Q1 miss and uncertainty around how long the EMEA inventory reset will weigh on sales (with spillover risk into Q2). Positives include strong cash flow/cash position, continued growth in Americas/APAC, and the bone marrow application expanding the addressable market, but investors are currently focused on recovery timing and margins.
Why HOLD ?
Hold: the company remains profitable with a strong balance sheet, but Q1 highlighted higher-than-expected revenue/margin volatility and distribution-channel risk in EMEA. Waiting for evidence of normalized EMEA ordering and Q2 stabilization is prudent before adding, while the bone marrow FDA pathway remains a meaningful upside catalyst later in 2026.
- Maintain the position; consider adding only after (1) Q2/Q3 confirmation that EMEA ordering normalizes and (2) clear commercial traction for the bone marrow application (including US regulatory progress).
Recent News
- Since the prior analysis, on 5 June 2026 the board appointed Steve Ferguson as CEO with immediate effect; former CEO Simon Østergaard will remain during a transition period. No new financial reports, equity raises, M&A, or regulatory readouts were identified. The next key datapoint is the Q2 report in mid-July 2026.
Bull case
- **Q1 report (24 Apr 2026)** could confirm continued strong organic growth, especially in the Americas.
- **Proposed SEK 2.75 dividend** may support investor interest and total return.
Unlock to read more →
Bear case
- **FX headwinds** may weigh on reported growth and margins.
Unlock to read more →
Catalysts
15 Aug 2026 — Bone Marrow: visible revenue impact
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of CellaVision AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.